CN113368209A - New application of astragalus-leech capsule in preparation of medicine for treating primary hypertension - Google Patents

New application of astragalus-leech capsule in preparation of medicine for treating primary hypertension Download PDF

Info

Publication number
CN113368209A
CN113368209A CN202110641504.1A CN202110641504A CN113368209A CN 113368209 A CN113368209 A CN 113368209A CN 202110641504 A CN202110641504 A CN 202110641504A CN 113368209 A CN113368209 A CN 113368209A
Authority
CN
China
Prior art keywords
astragalus
parts
leech
capsule
new use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110641504.1A
Other languages
Chinese (zh)
Other versions
CN113368209B (en
Inventor
王喜军
闫广利
孙辉
杨乐
白璧炜
车延柠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin traditional Chinese medicine four factory Co.,Ltd.
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110641504.1A priority Critical patent/CN113368209B/en
Publication of CN113368209A publication Critical patent/CN113368209A/en
Application granted granted Critical
Publication of CN113368209B publication Critical patent/CN113368209B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/62Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • A61K35/64Insects, e.g. bees, wasps or fleas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482Cassia, e.g. golden shower tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704Polygonum, e.g. knotweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734Crataegus (hawthorn)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/902Sparganiaceae (Bur-reed family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Insects & Arthropods (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a new application of astragalus-leech capsules in preparing a medicament for treating primary hypertension. The astragalus-leech capsule is composed of astragalus, polygonum multiflorum, cassia seed, hawthorn, peach kernel, curcuma zedoary, rhizoma sparganii, leech and ground beeltle, the traditional Chinese medicines in the formula are mutually reinforced and mutually exclusive, and the astragalus-leech capsule conforms to the compatibility principle of 'monarch, minister, assistant and guide' and has the functions of tonifying qi, removing blood stasis and dredging collaterals. Proved by tests, the astragalus-leech capsule can continuously and stably reduce the hypertension and obviously recover the integral metabolic function of an organism, and is an effective medicament for treating the primary hypertension.

Description

New application of astragalus-leech capsule in preparation of medicine for treating primary hypertension
Technical Field
The invention relates to a new application of astragalus-leech capsules in preparing a medicament for treating primary hypertension, and belongs to the technical field of application of traditional Chinese medicines.
Background
Essential hypertension is a comprehensive disease which is mainly characterized by the increase of systemic arterial pressure and is caused by the decompensation of the normal blood pressure regulation mechanism of the body under the action of a plurality of acquired environmental factors under a certain genetic background. Essential hypertension accounts for more than 95 percent of total hypertension, is the first risk factor for inducing people to have cardiovascular and cerebrovascular events, effectively controls blood pressure and treats essential hypertension, and is an important medical problem for maintaining human health.
The chemical medicine is the main medicine for clinically treating hypertension at present due to the characteristics of clear action mechanism, quick effect and strong action, and comprises a calcium channel blocker, an angiotensin converting enzyme inhibitor, an angiotensin receptor antagonist, a diuretic and a beta receptor blocker. In order to fully exert the complementary action mechanism of the medicaments to increase the curative effect, ensure that the blood pressure reaches the standard quickly, simultaneously reduce contraindications, malaise and side effects generated in the single medicament application process and keep longer action time, the combined application of the antihypertensive medicaments becomes the basic method of the antihypertensive treatment (revised committee of Chinese guidelines for preventing and treating hypertension in 2018, revised edition of the Chinese guidelines for preventing and treating hypertension in 2018, prevention and treatment of cardiovascular and cerebrovascular diseases, 2019.19(1): 1-44.). Therefore, a fixed-ratio compound preparation (CN105832731B, CN103239723B and CN102008711B) consisting of the medicines is invented.
However, essential hypertension is a complex disease with the combined action of genetic factors and acquired environmental factors, chemical drugs mainly aim at a certain link of pathological changes in the disease process of hypertension, the action path and the action target point are relatively single, although blood pressure can be quickly reduced, blood pressure management is complex, and improvement of hypertension complications cannot be considered. The traditional Chinese medicine regulates the balance of yin and yang and deficiency and excess of qi and blood of an organism, corrects the dysfunction of the organism and treats the hypertension from multiple components, multiple links and multiple targets by treatment based on syndrome differentiation. The prescription (Chinese herbal compound) is a medicine used in the clinical practice of traditional Chinese medicine, and is formed by matching a plurality of traditional Chinese medicines through seven emotions and combination and monarch, minister, assistant and guide; a single Chinese medicine is only the raw material for composing a prescription, and the curative effect of the Chinese medicine is expressed by the prescription according to the syndrome. Therefore, the traditional Chinese medicine compound for treating hypertension has the advantages that on one hand, the prescription function is not only simple addition of the antihypertensive effect of a single traditional Chinese medicine, but also the pharmacological effect is the integral effect of a plurality of traditional Chinese medicines; on the other hand, the traditional Chinese medicines composing the prescription do not all have pharmacological action of reducing blood pressure. The invention discloses a astragalus-leech capsule which has obvious effect of treating essential hypertension, and the prescription is composed of astragalus, leech, ground beeltle, peach kernel, rhizoma sparganii, curcuma zedoary, hawthorn, cassia seed, polygonum multiflorum and other traditional Chinese medicines, and has the functions of tonifying qi, removing blood stasis and realizing a passage.
The astragalus-leech capsule is produced by Haerbin traditional Chinese medicine four factories Limited company, the number of the currently executed national drug standard is WS-5431(B-0431) -2014Z, the approved functions and main indications are tonifying qi, removing blood stasis and dredging collaterals, and the astragalus-leech capsule is clinically used for treating hyperlipidemia, qi deficiency and blood stasis. Through clinical research in recent years, the application range of the astragalus-leech capsule is further expanded, and documents report that the astragalus-leech capsule has satisfactory clinical observation on stable angina pectoris (Penglaangli, and the like, the astragalus-leech capsule has satisfactory clinical observation on stable angina pectoris [ J ]. Heilongjiang traditional Chinese medicine 2014,5: 14-15.). The astragalus leech capsule for treating the essential hypertension and the pharmacological action of lowering the blood pressure are not reported so far, and the invention discovers the new application of the medicament in treating the essential hypertension through experimental research.
The invention discloses a new application of astragalus-leech capsules in a medicament for treating primary hypertension. The astragalus-leech capsule is composed of astragalus, polygonum multiflorum, cassia seed, hawthorn, peach kernel, curcuma zedoary, rhizoma sparganii, leech, ground beeltle and other medicinal ingredients, the traditional Chinese medicines in the formula are mutually reinforced and mutually guided, and the astragalus-leech capsule conforms to the compatibility principle of 'monarch, minister, assistant and guide' and has the functions of tonifying qi, removing blood stasis and dredging collaterals. Proved by tests, the astragalus-leech capsule can continuously and stably reduce the hypertension and remarkably recover the integral metabolic state of an organism, and is an effective medicament for treating the primary hypertension.
Disclosure of Invention
The invention aims to solve the technical problem of providing a new application of astragalus-leech capsules in preparing a medicament for treating primary hypertension in order to overcome the defects of the prior art.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
a new use of QIZHI Capsule in preparing medicine for treating essential hypertension is provided.
The astragalus leech capsule can obviously reduce the systolic blood pressure of the essential hypertension.
The astragalus leech capsule can regulate the physiological function of the organism of the essential hypertension.
The physiological functions of the body include weight gain and body metabolic rate regulation (i.e. reduction).
The dosage of the astragalus-leech capsule is 1-4 times of the dosage of the astragalus-leech capsule for clinically treating hyperlipemia.
The astragalus-leech capsule is prepared from the following raw material medicines in parts by weight: 100-400 parts of astragalus membranaceus, 40-160 parts of leech, 75-300 parts of peach kernel, 75-300 parts of polygonum multiflorum, 55-220 parts of curcuma zedoary, 55-220 parts of rhizoma sparganii, 62.5-250 parts of semen cassiae, 62.5-250 parts of hawthorn and 15-60 parts of ground beetle.
The astragalus and leech capsule comprises 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of polygonum multiflorum, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of cassia seed, 125 parts of hawthorn and 30 parts of ground beetle.
The preparation method of the astragalus-leech capsule comprises the following steps:
step one, weighing leeches, curcuma zedoary and rhizoma sparganii according to a proportion, and crushing into fine powder;
step two, weighing the astragalus, the peach kernel, the polygonum multiflorum, the cassia seed, the hawthorn and the ground beetle according to the proportion, adding water for decocting twice, adding 10 times of water for the first time, adding 8 times of water for the second time, decocting for 2 hours each time, combining decoction liquids, filtering, and concentrating the filtrate to thick paste with the relative density of 1.30-1.35;
and step three, adding the fine powder obtained in the step one into the thick paste obtained in the step two, uniformly mixing, drying at 50-60 ℃, crushing, and encapsulating to obtain the capsule.
The relative density of 1.30 to 1.35 is a relative density at 80 ℃.
The formulation of the astragalus-leech capsule can be replaced by granules, tablets, powder or pills.
The formula of the astragalus-leech capsule for treating primary hypertension disclosed by the invention has the characteristics of mutual reinforcement and mutual guide of traditional Chinese medicines and the principle of monarch, minister, assistant and guide of a prescription. The formula mainly uses the astragalus root which has the effects of tonifying qi and invigorating yang, aims at invigorating qi and promoting blood circulation, removes stasis and removes meridian obstruction, and is a monarch drug; leech and ground beeltle mutually reinforced are used for breaking blood and removing stasis and eliminating mass, zedoary and rhizoma sparganii mutually reinforced are used for breaking blood and removing stasis, eliminating mass and removing stasis, promoting qi circulation and relieving pain, peach kernel breaks blood and removes stasis to moisten dryness, three groups of blood-breaking and stasis-removing medicines are further mutually reinforced and used, and are compatible with qi-tonifying medicine astragalus to treat body deficiency and long-standing retention of blood stasis, and the three groups of blood-breaking and stasis-removing medicines are used as ministerial medicines; the polygonum multiflorum is used for detoxifying, moistening the intestines and relaxing the bowels, the cassia seed is used for clearing heat, moistening the intestines and relaxing the bowels, the hawthorn is used for promoting qi circulation and dissipating blood stasis, the three medicines are mutually reinforced, the turbid descending and detoxifying are carried out, and the three medicines are compatible with the blood-breaking and stasis-dissipating medicines to help dissipate blood stasis and promote tissue regeneration, so that the polygonum multiflorum is used as a messenger medicine; in the formula, the qi tonifying medicine is mutually compatible with a plurality of blood breaking and stasis removing medicines and turbidity lowering and toxin expelling medicines, so that qi and blood are vigorous and moved, blood stasis is removed and collaterals are cleared, qi is tonified without stagnation, blood is broken without hurting vital qi, the medicines are combined to play the functions of tonifying qi, removing blood stasis and dredging collaterals, and the traditional Chinese medicine is used for treating the primary hypertension qi deficiency and blood stasis syndrome.
The invention discloses a new application of astragalus-leech capsules in preparing medicaments for treating primary hypertension, wherein the medicament dosage form of the capsules also comprises one of granules, powder, tablets and pills, and pharmaceutically acceptable auxiliary materials, such as fillers, such as starch, lactose, mannose, chitin, microcrystalline cellulose, sucrose and the like, are added when the dosage forms are prepared in order to realize the dosage forms; disintegrating agents such as starch, microcrystalline cellulose, crospovidone, low-substituted hydroxypropylcellulose, and croscarmellose sodium; lubricants such as magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; binders such as starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, and the like; saccharin sodium, aspartame, sucrose, sodium cyclamate, etc.
The new application of the astragalus-leech capsule disclosed by the invention in preparing the medicine for treating the primary hypertension has the following remarkable advantages: compared with other patents of the invention, the invention treats the diseases from the aspects of liver-yang hyperactivity (CN1283275C), yin deficiency and yang hyperactivity (CN 103127421B), liver-kidney yin deficiency (CN103989817B), phlegm-damp obstruction in middle (CN105213822B) and the like, and the invention adopts a treatment method of tonifying qi, removing blood stasis and dredging collaterals to form a formula of astragalus-leech capsules aiming at the pathogenesis of primary hypertension and blood stasis; the formula composition of the astragalus-leech capsule conforms to the compatibility theory of 'monarch, minister, assistant and guide' and 'seven emotions and combination' of traditional Chinese medicine prescriptions, the qi-tonifying medicine is matched with the blood-breaking and blood stasis-removing medicine and the turbidity-reducing and toxin-expelling medicine in a mutual guide way, the blood-breaking and blood stasis-removing medicine and the turbidity-reducing and toxin-expelling medicine are matched in a mutual reinforcement way, the qi-tonifying medicine is the monarch, the blood-breaking and blood stasis-removing medicine is the minister, the turbidity-reducing and toxin-expelling medicine is the assistant, the qi-invigorating and blood circulation-promoting, and the stasis-removing and collaterals-dredging, and is used for treating the primary hypertension qi deficiency and blood stasis; animal experiments prove that the astragalus-leech capsule not only can stably and obviously reduce the blood pressure which is more than 30mmHg within the treatment period of 4 weeks, but also can recover the disordered metabolic network and the body weight of a hypertensive rat to normal level, thereby being beneficial to recovering the integral physiological function of the body and embodying the integral treatment advantage of the traditional Chinese medicine.
Drawings
FIG. 1 is a graph showing the trend of the change in systolic blood pressure of rats of the model group (SHR group) and the normal control group (WKY group) at 4-13 weeks of age (P <0.01 compared with the normal control group);
FIG. 2 is a graph showing the trend of change of systolic pressure of rats in 13-17 weeks of age in a model control group (SHR group), a normal control group (WKY group), a high-dose group of astragalus-leech capsules, a medium-dose group of astragalus-leech capsules, a low-dose group of astragalus-leech capsules and an aspirin control group (P is less than 0.01 compared with the normal control group and P is less than 0.01 compared with the model control group);
FIG. 3 is a graph showing the trend of the change in body weight of rats at 4-13 weeks of age in the control group (SHR group) and the normal control group (WKY group) according to the present invention (P <0.01, P <0.05 compared with the normal control group).
FIG. 4 shows the control group (SHR group) and the normal control group (WKY group) of the present inventionThe weight change trend chart of the rats in the astragalus-leech capsule high dose group, the astragalus-leech capsule medium dose group, the astragalus-leech capsule low dose group and the aspirin control group at the age of 13-17 weeks (compared with a normal control group, P is less than 0.01; compared with a model control group,##P<0.01)。
FIG. 5 is a score chart of PCA analysis of the urine metabolism network of rats with astragalus leech capsules for treating essential hypertension.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more clear, the present invention is further described in detail below with reference to the accompanying drawings and embodiments. The specific embodiments described herein are merely illustrative of the invention and are not intended to be limiting.
Example 1:
a new use of QIZHI Capsule in preparing medicine for treating essential hypertension is provided.
The astragalus leech capsule can obviously reduce the systolic blood pressure of the essential hypertension.
The astragalus leech capsule can regulate the physiological function of the organism of the essential hypertension.
The physiological functions of the organism comprise weight gain and body metabolic network adjustment.
The dosage of the astragalus-leech capsule is 1-4 times of the dosage of the astragalus-leech capsule for clinically treating hyperlipemia.
The astragalus and leech capsule comprises 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of polygonum multiflorum, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of cassia seed, 125 parts of hawthorn and 30 parts of ground beetle.
The preparation method of the astragalus-leech capsule comprises the following steps:
step one, weighing leeches, curcuma zedoary and rhizoma sparganii according to a proportion, and crushing into fine powder;
step two, weighing the astragalus, the peach kernel, the polygonum multiflorum, the cassia seed, the hawthorn and the ground beetle according to the proportion, adding water for decocting twice, adding 10 times of water for the first time, adding 8 times of water for the second time, decocting for 2 hours each time, combining decoction liquids, filtering, and concentrating the filtrate to thick paste with the relative density of 1.30-1.35;
and step three, adding the fine powder obtained in the step one into the thick paste obtained in the step two, uniformly mixing, drying at 50-60 ℃, crushing, and encapsulating to obtain the capsule.
The relative density of 1.30 to 1.35 is a relative density at 80 ℃.
The formulation of the astragalus-leech capsule can be replaced by granules, tablets, powder or pills.
The effect of the astragalus leech capsule for treating essential hypertension is further illustrated by the following experiments.
The essential Hypertension Rat (SHR) is a hereditary Hypertension model Rat, the pathogenesis and development changes of which are close to those of human beings, and the blood pressure level is higher and stable, so the SHR is an internationally accepted Hypertension animal model at present. The experiment adopts the animal model to research the regulation and control of the astragalus leech capsule on the hypertension, and the antihypertensive effect and the antihypertensive strength of the astragalus leech capsule are determined. And the metabolic networks of SHR rats before and after the treatment of the astragalus leech capsule are analyzed by utilizing a metabonomics technology, and the regulation and control of the drug on the overall function of the essential hypertension rat model are systematically explained.
First, experimental material
1. Instrument for measuring the position of a moving object
A constant temperature type noninvasive blood pressure measuring instrument (ZH200, anhuizhua bio instruments ltd); ultra high performance liquid chromatography (Acquity UPLC, Waters corporation, usa); high resolution mass spectrometer (Synapt G2/Si-HDMS, Waters, USA); omics data processing software Progenisis QI (Waters corporation, usa).
2. Reagent
Astragalus leech capsule (provided by Harbin four Chinese medicine factories), aspirin effervescent tablet (specification 0.1g, Aslicon pharmaceutical Co., Ltd.), sodium carboxymethylcellulose (Tanskin Seisaku Seisakusho chemical Co., Ltd.).
3. Laboratory animal
Essential hypertensive rat (SHR), male; the normal blood pressure control animals of WKY rat, male and SHR, which are control strains of hypertensive rat, are provided by Beijing Wintolite laboratory animal technology GmbH, license number: SCXK (Kyoto) 2016-. The breeding temperature is 24 +/-2 ℃, the humidity is 65-75%, the light is shielded for 12 hours, the illumination is carried out for 12 hours, and drinking water is freely taken.
Second, Experimental methods
1. Preparation of dosing samples
1.1 preparation of Astragalus leech capsule medicine gastric juice
Weighing three parts of fine powder of astragalus and leech capsule contents: 32.4g, 64.8g and 129.6g are respectively and uniformly mixed with 1000mL of sodium carboxymethylcellulose (CMC-Na) solution to prepare the astragalus-leech capsule medicament gastric juice with the concentration of 32.4mg/mL, 64.8mg/mL and 129.6mg/mL, which are respectively 1, 2 and 4 times of the dose approved by the astragalus-leech capsule for clinically treating the hyperlipoidemia.
1.2 preparation of Aspirin gastric juice
The common dosage of aspirin anticoagulant is 100 mg/day, and 2 times of the dosage is converted into the administration dosage of rats to prepare aspirin gastric perfusion. 36 aspirin effervescent tablets (each tablet contains 0.1g of aspirin) are taken and put into 20mL of distilled water, after the aspirin effervescent tablets are completely dissolved, CMC-Na solution is slowly added, the mixture is continuously stirred until the solution is uniform, the volume is fixed to 1000mL, and the aspirin gastric juice with the concentration of 3.6mg/mL is prepared.
2. Grouping and administration of laboratory animals
40 male SHR rats, randomly divided into 5 groups of 8: model control group, high-dose administration group of astragalus leech capsule, medium-dose administration group of astragalus leech capsule, low-dose administration group of astragalus leech capsule and aspirin administration group. Male WKY rats 8 were normal controls only. Rats in each group started on a normal diet from the 4 th week of age; starting from the age of 13 weeks, rats in each administration group are intragastrically administered with the corresponding drug by a gastric lavage fluid according to 1.0mL/100g, and are continuously administered for 4 weeks, and rats in a normal control group and a model control group are intragastrically administered with the corresponding dose of CMC-Na solution. The normal control group was WKY rats, male.
3. Measurement of blood pressure and body weight
The systolic pressure is measured noninvasively by adopting a rat tail artery blood pressure analysis system. The rats of the normal control group and the model control group measure the systolic pressure and the body weight of the tail artery every week from the age of 4 weeks; the tail arterial systolic pressure and body weight of rats of each administration group were measured from week 13.
4. Determination of urine metabolic network
4.1 urine sample Collection and processing
Rats 14-17 weeks old were collected overnight for 12 hours urine weekly, centrifuged (4 ℃, 13000r/min, 10min), and stored at-80 ℃. The samples were thawed at room temperature for analysis, diluted 1-fold with distilled water, vortexed for 10s, centrifuged (4 ℃, 13000r/min, 10min), and the supernatant was taken for UPLC-G2-Si-HDMS analysis.
4.2 conditions of analysis
4.2.1 chromatographic conditions
A chromatographic column: waters ACQUITY UPLCTMHST 3(100 mm. times.2.1 mm, 1.8 μm); mobile phase A: 0.1% formic acid in acetonitrile, mobile phase B: 0.1% aqueous formic acid, linear gradient elution procedure is shown in table 1; column temperature: 45 ℃; sample introduction amount: 1 μ L.
TABLE 1 UPLC mobile phase gradient elution method for rat urine samples
Figure BDA0003108013160000081
4.2.2 Mass Spectrometry conditions
Electrospray ion source (ESI); capillary voltage 2500V; the taper hole voltage is 40V; ion source temperature: 110 ℃; extracting the voltage of the taper hole to be 5.0V; the temperature of desolventizing gas is 400 ℃; the flow rate of the taper hole is 50L/h; the desolventizing agent gas flow is 800L/h; leucine-enkephalin is adopted for accurate mass measurement; mass scan range: 50-1200 Da.
Second, experimental results
1. Changes in blood pressure
The change in systolic blood pressure of rats in the model group before the administration of the drug and the normal control group is shown in Table 2 and FIG. 1. The systolic pressure of the rats in the normal control group is not obviously changed within the age of 4-13 weeks; compared with the normal control group rats, the model group rats have significantly higher systolic pressure from 5 weeks of age than the normal control group (P <0.01) and reach 193.15 +/-4.52 mmHg by 13 weeks of age.
Table 2 rat 4-13 weeks old systolic blood pressure (mmHg) change (mean ± standard deviation, n ═ 8)
Figure BDA0003108013160000082
Note: p <0.05, P < 0.01.
The blood pressure changes of the model group and the normal control group after the administration of the treatment are shown in Table 3 and FIG. 2. The systolic pressure of the rats in the model group aged 13-17 weeks is continuously increased, and the average systolic pressure at the age of 17 weeks is 202.41 +/-3.35 mmHg; the normal control group rats have no obvious change of systolic pressure, and the average systolic pressure is 128.33 +/-5.68 mmHg. In each administration group, the high, medium and low doses of the astragalus leech capsule can obviously reduce the systolic pressure of rats, and after one week of administration, the astragalus leech capsule has obvious curative effect, and the systolic pressure of three groups of rats is obviously reduced compared with that of a model group (P is less than 0.01). The high-dose antihypertensive effect of the astragalus-leech capsule is the best, the high-dose antihypertensive effect is obviously lower than that of a model group (P <0.01) when the astragalus-leech capsule is treated for 1 week, and the average systolic pressure is reduced to 163.75 +/-9.95 mmHg when the astragalus-leech capsule is administered for 4 weeks; the blood pressure reducing effect of the astragalus-leech capsule dose is only second to the high dose, the blood pressure reducing effect is obviously lower than that of a model group (P <0.01) when the astragalus-leech capsule is treated for 1 week, and the average systolic pressure of rats is reduced to 165.83 +/-7.37 mmHg when the astragalus-leech capsule is administered for 4 weeks; the low-dose antihypertensive effect of the astragalus-leech capsule is not as good as that of the high-dose and medium-dose capsules, but the systolic pressure (P is less than 0.01) of rats is remarkably reduced after 1 week of treatment, and the mean systolic pressure is reduced to 174.83 +/-3.77 mmHg after 4 weeks of treatment. Compared with the model group, the aspirin control group has no significant difference in systolic pressure at 2 weeks of treatment, the systolic pressure at 3 weeks and 4 weeks of treatment is significantly lower than that of the model group (P <0.01), and the mean systolic pressure at 4 weeks of treatment is reduced to 190.16 +/-1.57 mmHg. The result shows that aspirin with the pharmacological effects of inhibiting platelet aggregation and resisting thrombus can not effectively reduce blood pressure, and the traditional Chinese medicine compound astragalus and leech capsule with the functions of tonifying qi, removing blood stasis and dredging collaterals can effectively reduce blood pressure, and shows that the astragalus and leech capsule has a special blood pressure reducing effect.
TABLE 313-17 weeks old rat systolic blood pressure (mmHg) variation comparison (mean. + -. standard deviation, n ═ 8)
Figure BDA0003108013160000091
Note: p <0.05, P <0.01, compared to normal controls; compared with the model control group, # P <0.05, # P < 0.01.
2. Weight change
The body weight changes of rats in the model group before the administration of the drug and the normal control group are shown in Table 4 and FIG. 3. The weight of the model group rats steadily increases at 5-10 weeks of age, the growth rate is higher than that of the blank group, the growth rate of the model group rats decreases at 10 weeks of age, and the weight of the model group rats is obviously lower than that of the blank group at 13 weeks of age.
Table 4 comparison of body weight (g) changes at 4-13 weeks of age for each group of rats (mean ± sd, n ═ 8)
Figure BDA0003108013160000101
Note: p <0.05, P <0.01 compared to normal controls.
The body weight changes of rats in the model group and the normal control group after the administration of the treatment are shown in Table 5 and FIG. 4. At the beginning of 13-week-old administration, the body weight of each rat in the administration group is not significantly different from that of the model group, and is in the range of 244.46 +/-9.40 g, which is significantly lower than that of the normal control group rats (P < 0.01). The weight growth rate of rats of 13-17 weeks old and each administration group of the astragalus-leech capsule is higher than that of the model group, and tends to a normal control group. At the age of 17 weeks, the weight of the rats in each administration dose group of the astragalus-leech capsule is higher than that of the model group, has very significant difference (P is less than 0.01), and is close to that of a normal control group. The body weight of the 13-17 week-old aspirin administration group rats is not obviously different from that of the model group.
Table 5 comparison of body weight (g) changes at 13-17 weeks of age in each group of rats (mean ± sd, n ═ 8)
Figure BDA0003108013160000102
Figure BDA0003108013160000111
Note: p <0.05, P <0.01, compared to normal controls; compared to the model group, # P <0.05, # P < 0.01.
3. Regulation and control of primary hypertension rat metabolic network
The blood pressure reduction measurement result shows that the high-dose astragalus-leech capsule has a better blood pressure reduction effect, and in order to show the change of a rat metabolic network more clearly, a high-dose astragalus-leech capsule group, a model control group and a blank control group are selected for metabolic network analysis. Analyzing urine at week 17 of high dose group, model control group and normal control group of Astragalus leech capsule by using urine metabolite fingerprint analysis conditions to obtain UPLC-Q/TOF-MS data of rat urine of each group, extracting metabolite retention time, m/z and peak intensity data by using omics data processing software Progenetics QI (Waters, USA), and performing Principal Component Analysis (PCA) to obtain score map (Scores Plot) reflecting organism metabolic network change as shown in figure 5. Each point in the diagram represents each rat, and the position of each point in the diagram represents the spatial state of the metabolic network of the rat; in the figure, point C represents a normal control group rat, point M represents a model control group rat, point QH represents a astragalus leech capsule high-dose group rat, the point C and the point QH can be seen to be gathered into one type, and the point M is gathered into one type, which shows that the disordered metabolic network of the hypertensive rat is adjusted back to the normal rat after the astragalus leech capsule is used for treating, so that the physiological function of an organism can be recovered to a normal level while the astragalus leech capsule is used for reducing blood pressure, and the astragalus leech capsule not only can reduce blood pressure, but also can recover the whole physiological function of the organism by combining with the change of the weight of the rat.
Fourth, conclusion
The research utilizes an essential hypertension rat model to evaluate the treatment effect of the astragalus leech capsule on hypertension, and shows that the astragalus leech capsule can obviously reduce the blood pressure of essential hypertension rats, obviously increase the body weight of the hypertension rats, and call back the metabolic network of the organism of the hypertension rats, so that the essential hypertension can be effectively treated, and the integral physiological function of hypertension can be regulated.
Example 2:
this example differs from example 1 only in that: the astragalus-leech capsule is prepared from the following raw material medicines in parts by weight: 100 parts of astragalus, 40 parts of leech, 75 parts of peach kernel, 75 parts of fleece-flower root, 55 parts of zedoary, 55 parts of rhizoma sparganii, 62.5 parts of cassia seed, 62.5 parts of hawthorn and 15 parts of ground beetle.
Example 3:
this example differs from example 1 only in that: the astragalus-leech capsule is prepared from the following raw material medicines in parts by weight: 400 parts of astragalus, 160 parts of leech, 300 parts of peach kernel, 300 parts of fleece-flower root, 20 parts of zedoary, 220 parts of rhizoma sparganii, 250 parts of cassia seed, 250 parts of hawthorn and 60 parts of ground beetle.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.

Claims (10)

1. A new use of QIZHI Capsule in preparing medicine for treating essential hypertension is provided.
2. The new use according to claim 1, characterized in that: the astragalus leech capsule can obviously reduce the systolic blood pressure of the essential hypertension.
3. The new use according to claim 2, characterized in that: the astragalus leech capsule can regulate the physiological function of the organism of the essential hypertension.
4. The new use according to claim 3, characterized in that: the physiological functions of the organism comprise weight gain and metabolic rate regulation.
5. The new use according to claim 1, characterized in that: the dosage of the astragalus-leech capsule is 1-4 times of the dosage of the astragalus-leech capsule for clinically treating hyperlipemia.
6. The new use according to claim 1, characterized in that: the astragalus-leech capsule is prepared from the following raw material medicines in parts by weight: 100-400 parts of astragalus membranaceus, 40-160 parts of leech, 75-300 parts of peach kernel, 75-300 parts of polygonum multiflorum, 55-220 parts of curcuma zedoary, 55-220 parts of rhizoma sparganii, 62.5-250 parts of semen cassiae, 62.5-250 parts of hawthorn and 15-60 parts of ground beetle.
7. The new use according to claim 1, characterized in that: the astragalus and leech capsule comprises 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of polygonum multiflorum, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of cassia seed, 125 parts of hawthorn and 30 parts of ground beetle.
8. The new use according to claim 6 or 7, characterized in that: the preparation method of the astragalus-leech capsule comprises the following steps:
step one, weighing leeches, curcuma zedoary and rhizoma sparganii according to a proportion, and crushing into fine powder;
step two, weighing the astragalus, the peach kernel, the polygonum multiflorum, the cassia seed, the hawthorn and the ground beetle according to the proportion, adding water for decocting twice, adding 10 times of water for the first time, adding 8 times of water for the second time, decocting for 2 hours each time, combining decoction liquids, filtering, and concentrating the filtrate to thick paste with the relative density of 1.30-1.35;
and step three, adding the fine powder obtained in the step one into the thick paste obtained in the step two, uniformly mixing, drying at 50-60 ℃, crushing, and encapsulating to obtain the capsule.
9. The new use according to claim 8, characterized in that: the relative density of 1.30 to 1.35 is a relative density at 80 ℃.
10. The new use according to claim 8, characterized in that: the formulation of the astragalus-leech capsule can be replaced by granules, tablets, powder or pills.
CN202110641504.1A 2021-06-09 2021-06-09 New use of QIZHI Capsule in preparing medicine for treating essential hypertension Active CN113368209B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110641504.1A CN113368209B (en) 2021-06-09 2021-06-09 New use of QIZHI Capsule in preparing medicine for treating essential hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110641504.1A CN113368209B (en) 2021-06-09 2021-06-09 New use of QIZHI Capsule in preparing medicine for treating essential hypertension

Publications (2)

Publication Number Publication Date
CN113368209A true CN113368209A (en) 2021-09-10
CN113368209B CN113368209B (en) 2023-07-11

Family

ID=77573061

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110641504.1A Active CN113368209B (en) 2021-06-09 2021-06-09 New use of QIZHI Capsule in preparing medicine for treating essential hypertension

Country Status (1)

Country Link
CN (1) CN113368209B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391915A (en) * 2001-06-15 2003-01-22 刘宇晖 Chouxue qing capsule for reducing blood viscosity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391915A (en) * 2001-06-15 2003-01-22 刘宇晖 Chouxue qing capsule for reducing blood viscosity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
田学增等: "芪蛭胶囊治疗冠心病心绞痛临床观察", 《中医药学报》 *

Also Published As

Publication number Publication date
CN113368209B (en) 2023-07-11

Similar Documents

Publication Publication Date Title
CN100455291C (en) Notoginseng medicine composition for treating cardiac and cerebral vascular diseases
CN111110824B (en) Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN103989668A (en) Application of fructus forsythiae aglycone in preparing medicament for preventing or treating liver injury or liver failure
WO2021204170A1 (en) Active peptide derived from eupolyphaga sinensis walker and having blood lipid lowering function, and preparation method therefor and use thereof
CN114246918B (en) Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof
CN109125315A (en) Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity
Chun et al. Effect of antacids on absorption of clorazepate
CN100467025C (en) Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels
CN1931233B (en) Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases
CN113368209A (en) New application of astragalus-leech capsule in preparation of medicine for treating primary hypertension
CN106063791A (en) The application in preparing anti-inflammatory drug of the compositions of phillyrin, phillyrin derivant, phillyrin and phillygenol
CN109381455A (en) With the composition for adjusting blood glucose, blood lipid and blood pressure function
CN101450117B (en) Rheumatism treatment medicine composition, formulation and preparation method
CN101396435B (en) Traditional Chinese medicine for treating gastrosis and preparation method and use thereof
CN1331466C (en) Medicine preparation for treating liver and gallbladder disease and its preparing process
CN104688723A (en) Application of anhydroicaritin in preparation of medicine for treating anaemia
CN111166759A (en) A pharmaceutical composition for treating coronary heart disease
CN108057102B (en) Pharmaceutical composition for preventing or treating gouty arthritis, preparation method and application
CN104042613B (en) A kind of composition and the purposes in medicine thereof
CN114558047B (en) Traditional Chinese medicine composition for preventing and treating osteoporosis and preparation method thereof
CN115243774B (en) Pharmaceutical composition containing amlodipine, chlorthalidone and amiloride
CN114028449B (en) Traditional Chinese medicine compound medicine for treating fatty liver disease
CN115337348B (en) Traditional Chinese medicine composition for treating heat-accumulation blood vessels
CN1575803A (en) Application method of Aloe vera L. extract in preventing and curing diabetes
CN107213323B (en) Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20231030

Address after: 150025 North Nanjing Road, Limin Development Zone, Harbin City, Heilongjiang Province

Patentee after: Harbin traditional Chinese medicine four factory Co.,Ltd.

Address before: 150025 Harbin No.4 traditional Chinese Medicine Factory Co., Ltd., north of Nanjing Road, Limin Development Zone, Harbin, Heilongjiang Province

Patentee before: Che Yanning

TR01 Transfer of patent right